Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253147 · ClinicalTrials.gov registry record · NA
TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds
A NA study of Nasolabial Folds, Wrinkles, sponsored by Teoxane.
- Completed
- Registry status
- NA
- Development phase
- 140
- Enrollment target
- 4
- Study locations
NCT02253147: Completed NA study of Nasolabial Folds, Wrinkles, sponsored by Teoxane.
NCT02253147 is a NA study of Nasolabial Folds, Wrinkles that has completed, run by Teoxane. The registered enrollment target is 140 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02253147, a NA study of Nasolabial Folds, Wrinkles, has completed, sponsored by Teoxane.
- COMPLETED
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness and safety of TEOSYAL® RHA Ultra Deep versus Perlane-L® in the treatment of moderate to severe nasolabial folds. This is a controlled, randomized, double-blinded, within subject (split-face), multicenter, prospective clinical study.
Primary Outcome
WSRS (Wrinkle Severity Rating Scale) is a validated 5-point scale with 1 being 'absent' and 5 being 'extreme'. BLE =Blinded Live Evaluator
Conditions Studied
Interventions
- DEVICE TEOSYAL® RHA Ultra Deep
Study Locations (4)
California
- United States - Beverly Hills
Florida
- United States - Bradenton
North Carolina
- United States - Chapel Hill
Pennsylvania
- United States - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-05 |
| Phase | NA |
What the finished NCT02253147 record still lists
NCT02253147 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Nasolabial Folds, Wrinkles appearing as the primary indexed condition, and to 1 intervention - of which TEOSYAL® RHA Ultra Deep is the first listed.
NCT02253147 reports a single indexed study location in California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02253147 about?
NCT02253147 is a clinical study titled "TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds". The purpose of this study is to compare the effectiveness and safety of TEOSYAL® RHA Ultra Deep versus Perlane-L® in the treatment of moderate to severe nasolabial folds. This is a controlled, randomized, double-blinded, within subject (split-face), multicenter, prospective clinical study.
What is the current status of trial NCT02253147?
This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2014-09. Estimated completion is 2016-05.
What conditions does trial NCT02253147 study?
This clinical trial studies the following conditions: Nasolabial Folds, Wrinkles.
What interventions are being tested in trial NCT02253147?
The interventions under investigation include: TEOSYAL® RHA Ultra Deep (DEVICE).
Who is sponsoring clinical trial NCT02253147?
This trial is sponsored by Teoxane, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02253147 being conducted?
This trial has 4 study locations across California, Florida, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02253147's enrollment target sits among peer trials
140 713th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia